Tesamorelin
GHRH analogue, the clinically proven oneGrowth-hormone-releasing therapy with phase-3 evidence behind it, visceral fat, recovery, and body composition, monitored against your labs.
Mean reduction in visceral adipose tissue at 26 weeks in phase 3 trials, tesamorelin is the most clinically validated GHRH analogue available. Your consultant will be direct about what applies to your case. Full reference →
Who this is for
Adults with stubborn visceral fat, declining recovery, or body-composition goals where labs support GH-axis therapy. Candidacy is decided with your consultant against your history and IGF-1, never by a checkout flow.
How the program works
Your consultant goes through your goals, history, and whether this therapy is appropriate. If it isn't, you'll hear that instead.
An at-home blood draw establishes your baseline. Your pen ships cold-chain once your program is agreed.
A small dose before bed, timed to your natural GH pulse. Video review at week 6, messaging in between.
IGF-1 and symptoms reviewed against baseline. Together you decide: continue, adjust, or taper off with a plan.
Common questions
Sleep depth often shifts within weeks; body-composition changes are slower and tracked at your IGF-1 reviews. Your consultant measures rather than promises.
Both are GHRH analogues, but tesamorelin carries the strongest clinical evidence in the class, including phase 3 trials, and is the one usually reached for when visceral fat is the target.
Your program is quoted in full after your consultation, before anything is supplied. There is no set program price because there is no off-the-shelf product: dose, timing and monitoring differ per patient.
Tesamorelin is the international non-proprietary name for a synthetic 44-amino-acid analog of growth hormone releasing hormone (GHRH) with a trans-3-hexenoic acid modification at the N-terminus. The developmental code was TH9507. The proprietary brand name is Egrifta (and Egrifta SV for the more recent sterile water variant). All four names describe the same compound.
Tesamorelin is used in research as a tool to probe growth hormone axis biology with preserved pulsatility, visceral adipose tissue metabolism, lipid signalling, and liver fat biology. The Falutz NEJM 2007 trial and the Stanley JAMA 2014 trial provide the principal published clinical context. The compound's established clinical evidence base distinguishes it from most other research peptides.
Stimulating release, not replacing it
Tesamorelin binds the growth hormone releasing hormone receptor (GHRHR) on anterior pituitary somatotroph cells, stimulating the synthesis and pulsatile release of growth hormone. The full 44-amino-acid sequence allows close engagement with the native receptor.
Tesamorelin preserves the physiological pulsatility of growth hormone secretion, in contrast to exogenous GH administration which suppresses endogenous pulsatile release. The pulsatility preservation is mechanistically relevant to downstream IGF-1 signalling.
The trans-3-hexenoic acid modification at the N-terminus protects tesamorelin from rapid degradation by dipeptidyl peptidase-IV (DPP-IV), the enzyme that limits native GHRH plasma half-life to roughly seven minutes. The modification is the structural reason tesamorelin has a clinically useful pharmacokinetic profile.
Falutz and colleagues (N Engl J Med, 2007;357(23):2359-2370) reported reduced visceral adipose tissue measured by CT scan in HIV-infected adults with abdominal lipodystrophy. The visceral fat reduction is the basis for the FDA approval indication.
Tesamorelin is also searched as TH9507, Egrifta, GHRH (1-44) analog.